1 / 21

Issues and lesson learned as a NRL in TB Management (GENETUP)

Issues and lesson learned as a NRL in TB Management (GENETUP). Dr. Bhabana Shrestha NATA/GENETUP 14 th July 2014. German Nepal TB project ( GENETUP). Providing the diagnostic & treatment services since 27 years Pioneer of Directly Observed Treatment Short Course (DOTS)

engelbert-nathanial
Download Presentation

Issues and lesson learned as a NRL in TB Management (GENETUP)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Issues and lesson learned as a NRL in TB Management (GENETUP) Dr. BhabanaShrestha NATA/GENETUP 14th July 2014

  2. German Nepal TB project (GENETUP) • Providing the diagnostic & treatment services since 27 years • Pioneer of Directly Observed Treatment Short Course (DOTS) • Pioneer of diagnosis of drug resistant tuberculosis (DR TB) • Alliance partner of NTP, for the DR-TB management program, ( DR-TB centre & National Reference laboratory for Culture & DST)

  3. GENETUP LABORATORY Facilities • Microscopy by LED microscope • Conventional culture and DST on first line and second line drugs • Gene Xpert/MTB/RIF • Molecular Line Probe assay for first line (H&R) and second line (Flq & AI) • Research puupose: • Bactec MGIT • Genotyping of MTB (only for research purpose)

  4. MDR-TB suspects - definition • Failures of cat. I and cat. II • Initially SS+ patients who are still positive after three months of DOTS and/or are doing poorly clinically (persistent cough, fever, loss of weight, tiredness, etc.) • People living with HIV (at the start of ANY anti-TB treatment to avoid MDR-related mortality) • Patients starting cat. II for any reason • Close contacts of proven X/MDR-TB cases

  5. Where to refer ?? • National Reference Lab, NTC, Thimi • National Reference lab, GENETUP,Kalimati • Nearest Gene Xpert Centres

  6. Result of MDR Survey in Nepal

  7. Result of XDR Survey in Nepal

  8. Diagnostic Gap Based on DRS-2011, 996 new MDR-TB develops every year • 550 MDR-TB cases among new smear-positive patients • 446 MDR-TB cases among estimated previously treated cases • 80 XDR-TB cases • Out of the estimated 996 MDR-TB cases, only 271 (27.3%) • Out of the estimated 80 XDR-TB cases, only 26 (33%) WERE ON TREATMENT.

  9. Case Finding (Pre-XDR/XDR-TB)

  10. Treatment Out Come of XDR-TB

  11. High initial quinolone resistant among the MDR-TB Initial SLDST of MDR patients N=169 (Dec 2013-July2014) Quinolone KamamycinCapreomycin n Susceptible Susceptible Susceptible 109(64.4%) ResistantSusceptible Susceptible 56 (33.1%) Resistant Resistant Resistant 1(0.6%) SensitiveResistant Resistant 3(1.7%) Total 169

  12. Result of Gene Xpert Gene Xpert test result at GENETUP Lab (Feb 2014-July 2014) TotalTB detected TB not detected MDR • Smear Positive 215202 13 55 (27.2%) • Smear Negative 471142 (30.1%) 329 20 (14.0%) • Error 14 (2%) • Total 700 Remarks: Gene Xpertdetects high case notification among the smear negatives

  13. MDR Diagnostic Method verses enrollment

  14. A High Case Load at GENETUP DR CENTER Enrollment ( 070/071) • MDR: • Total Nationwide Registered Cases 302 • GENETUP 87 (28.8%) • XDR: • Total Nationwide Registered Cases 31 • GENETUP 19 (61.2%)

  15. Challenges in DR TB management program 1- Pre-XDR, XDR & XXDR TB 2- 22 cases were tested for 11 drugs( KM, CM, AM, Ofx, Moxi, CS, PTH, PZA, Cfz, Lzd, PAS) Resistant to Lzd- 4.5 %(1case) High number of resistance to PZA & PTH (95.5 % & 90%) Cfz (63 %) PAS (45 %) CS (23 %) Remark: these are serious public health problem and need isolation and right treatment to prevent further transmission

  16. Think ,Think and Rethink • Alarming situation of DR TB cases • Management of the XXDR TB cases

  17. ISSUES • Workload at the NRL, GENETUP -Covering 8 DR treatment centers -Testing of 3 sputum specimens instead of 2 sputum specimens -Overload of Gene Xpert testing request • Weak Cross Referral / Tracking Mechanism • Diagnostic limitation of EP DR TB • Lack of motivating factors to the staff

  18. Problems • Inadequate budget for SLDST • Inadequate supply of ancillary drugs • Management of adverse effects of second line drugs • Management of MOTT

  19. Any Question ? ? ?

  20. Thank you Thank you

More Related